1175 related articles for article (PubMed ID: 29094609)
1. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Smyth E; Thuss-Patience PC
Oncol Res Treat; 2018; 41(5):272-280. PubMed ID: 29705787
[TBL] [Abstract][Full Text] [Related]
4. [New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].
Quesada S; Vaflard P
Bull Cancer; 2022 Feb; 109(2):111-113. PubMed ID: 34998526
[No Abstract] [Full Text] [Related]
5. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Fornaro L; Olesiński T; Caglevic C; Chung HC; Muro K; Goekkurt E; Mansoor W; McDermott RS; Shacham-Shmueli E; Chen X; Mayo C; Kang SP; Ohtsu A; Fuchs CS;
Lancet; 2018 Jul; 392(10142):123-133. PubMed ID: 29880231
[TBL] [Abstract][Full Text] [Related]
7. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Tabernero J; Bang YJ; Van Cutsem E; Fuchs CS; Janjigian YY; Bhagia P; Li K; Adelberg D; Qin SK
Future Oncol; 2021 Aug; 17(22):2847-2855. PubMed ID: 33975465
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma.
Smyth EC; Petty RD
Lancet; 2018 Jul; 392(10142):97-98. PubMed ID: 29880232
[No Abstract] [Full Text] [Related]
9. Current status of ramucirumab in gastroesophageal adenocarcinoma.
Elimova E; Lin Q; Song S; Ajani JA
Future Oncol; 2017 Aug; 13(18):1585-1592. PubMed ID: 28436242
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
Qiu HB
Thorac Cancer; 2020 Dec; 11(12):3419-3421. PubMed ID: 33043992
[No Abstract] [Full Text] [Related]
11. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
Kulangara K; Zhang N; Corigliano E; Guerrero L; Waldroup S; Jaiswal D; Ms MJ; Shah S; Hanks D; Wang J; Lunceford J; Savage MJ; Juco J; Emancipator K
Arch Pathol Lab Med; 2019 Mar; 143(3):330-337. PubMed ID: 30028179
[TBL] [Abstract][Full Text] [Related]
13. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
14. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.
Pericay C; Rivera F; Gomez-Martin C; Nuñez I; Cassinello A; Imedio ER
Cancer Med; 2016 Dec; 5(12):3464-3474. PubMed ID: 27774774
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
[TBL] [Abstract][Full Text] [Related]
17. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
18. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Akin Telli T; Bregni G; Camera S; Deleporte A; Hendlisz A; Sclafani F
Cancer Lett; 2020 Jan; 469():142-150. PubMed ID: 31669518
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
20. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]